nd,
Martin JD, Bortey EB, et al. A comparison of cilostazol and
pentoxifylline for treating intermittent claudication. Am J Med
2000;109:523-30.
97. Effects of ramipril on cardiovascular and microvascular outcomes in
people with diabetes mellitus: results of the HOPE study and
MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation
Study Investigators. Lancet 2000;355:253-9.
98. Ahimastos AA, Walker PJ, Askew C, Leicht A, Pappas E,
Blombery P, et al. Effect of ramipril on walking times and quality of
life among patients with peripheral artery disease and intermittent
claudication: a randomized controlled trial. JAMA 2013;309:
453-60.
99. Brass EP, Koster D, Hiatt WR, Amato A. A systematic review and
meta-analysis of propionyl-L-carnitine effects on exercise performance
in patients with claudication. Vasc Med 2013;18:3-12.
100. Delaney CL, Spark JI, Thomas J, Wong YT, Chan LT,
Miller MD. A systematic review to evaluate the effectiveness of
carnitine supplementation in improving walking performance
among individuals with intermittent claudication. Atherosclerosis
2013;229:1-9.
101. Watson L, Ellis B, Leng GC. Exercise for intermittent claudication.
Cochrane Database Syst Rev 2008;(4):CD000990.
102. Gardner AW, Forrester L, Smith GV. Altered gait proﬁle in subjects
with peripheral arterial disease. Vasc Med 2001;6:31-4.
103. American College of Sports Medicine Position Stand and American
Heart Association. Recommendations for cardiovascular screening,
stafﬁng, and emergency policies at health/ﬁtness facilities. Med Sci
Sports Exerc 1998;30:1009-18.
104. Aung PP, Maxwell HG, Jepson RG,